We have a balanced and growing team supported by some of the world’s leading experts in HIV/AIDS and immunology.

Our executive team is composed of entrepreneurial and creative managers. They are supported by an advisory board that includes leading scientists and physicians from world renowned research laboratories, teaching hospitals, academic institutions and pharmaceutical companies.

Select a biography below for more information on each individual.

Haig Keledjian, CEO, President

Monica Ord, SVP Communications and Corporate Development

Karen Newell, PhD, Advisor

Michael Capizzano, Consultant

Sam Golube, MD, Advisor

Bada Pharisi, Advisor

About Us

Contact Us

Corporate Governance and Board of Directors

Advisory Board

Viral Genetics' (OTC Bulletin Board: VRAL - News) first double-blind, placebo-controlled study of VGV-1 for the treatment of HIV and AIDS showed positive results consistent with four previous human trials of the drug. Results indicate statistically significant reductions in viral load (the amount of HIV in the blood) in some patients, only mild adverse events attributed to the drug, and a mechanism of action that appears to be markedly different than existing HIV therapies.

Viral Genetics is working toward a therapy that could have a positive impact on the large numbers of people infected with HIV, which in 2005 was estimated at 38.6 million people worldwide by UN AIDS (a joint United Nations Programme on HIV/AIDS).

Click here for more.